Insight2016-08-01T14:51:33-04:00
1002, 2021

Laidlaw Capital Markets served as Financial Advisor on the $115,000,000 Follow-On Offering for EyePoint Pharmaceuticals

By |February 10th, 2021|News, press release|

The Team at Laidlaw Capital Markets is pleased to have acted as Financial Advisor on the $115,000,000 Follow-On Offering, alongside Guggenheim and Cowen. This is the third transaction Laidlaw has been a part of with Read More...

702, 2020

Defiance ETFs LLC Rings The Closing Bell®

By |February 7th, 2020|News|

Laidlaw was proud to attend the closing bell ceremony at the NYSE yesterday. Defiance ETFs LLC is the first 5G ETF (NYSE Arca: FIVG) Alex Shtaynberger, Richard Calhoun and Keith Hassan from Laidlaw attended and were Read More...

502, 2020

Laidlaw served as Co-Manager on the $90mm Ziopharm Oncology (ZIOP) Follow-On Offering

By |February 5th, 2020|News, press release|

Laidlaw Capital Markets is pleased to announce today’s pricing of a $90,000,000 Follow-On Offering for Ziopharm Oncology (ZIOP). Laidlaw proudly served as Co-Manager alongside Jefferies, who was Sole-Book Runner on the transaction. See full Press Read More...

Ready to talk?

Lorem ipsum dolor sit amet, consectetur adipisicing elit mod tempor incididunt ut labore et dolore magna aliqua.

Go to Top